Exchange: NASDAQ·Updated 08:36 AM EDT
ALT logo

ALTAltimmune Inc

$2.97
$0.0063
(0.21%)
Pre-Market
Prev Close $2.98
EarningsAug 11
Mkt Cap$579.53M
Vol36,390.00

About ALT

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

About

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
57

Frequently Asked Questions

What is Market Cap of Altimmune Inc?
What is the 52-week high for Altimmune Inc?
What is the 52-week low for Altimmune Inc?
What is Altimmune Inc stock price today?
What was Altimmune Inc stock price yesterday?
What is the PE ratio of Altimmune Inc?
What is the Price-to-Book ratio of Altimmune Inc?
What is the 50-day moving average of Altimmune Inc?
How many employees does Altimmune Inc have?

Advertisement|Remove ads.

Advertisement|Remove ads.